Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Shares Outstanding (2019 - 2025)

Cyclerion Therapeutics has reported Shares Outstanding over the past 7 years, most recently at $3.8 million for Q3 2025.

  • Quarterly results put Shares Outstanding at $3.8 million for Q3 2025, up 50.71% from a year ago — trailing twelve months through Sep 2025 was $3.8 million (up 50.71% YoY), and the annual figure for FY2024 was $2.5 million, up 2.9%.
  • Shares Outstanding for Q3 2025 was $3.8 million at Cyclerion Therapeutics, up from $351037.0 in the prior quarter.
  • Over the last five years, Shares Outstanding for CYCN hit a ceiling of $43.3 million in Q3 2021 and a floor of $225000.0 in Q1 2023.
  • Median Shares Outstanding over the past 5 years was $2.5 million (2023), compared with a mean of $8.1 million.
  • Biggest five-year swings in Shares Outstanding: tumbled 94.98% in 2022 and later surged 1010.93% in 2024.
  • Cyclerion Therapeutics' Shares Outstanding stood at $2.2 million in 2021, then grew by 0.25% to $2.2 million in 2022, then increased by 13.71% to $2.5 million in 2023, then rose by 2.9% to $2.5 million in 2024, then surged by 49.82% to $3.8 million in 2025.
  • The last three reported values for Shares Outstanding were $3.8 million (Q3 2025), $3.1 million (Q2 2025), and $3.1 million (Q1 2025) per Business Quant data.